Back to Journals » Cancer Management and Research » Aims and Scope

Cancer Management and Research

ISSN: 1179-1322


Aims and Scope

Editor-in-Chief:

Cancer Management and Research is part of our Elevate Series. This means that you will receive a concierge-level publishing experience, including dedicated support from our expert in-house Editorial team.

Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients.

Cancer Management and Research will no longer consider meta-analyses for publication.

Specific topics covered in the journal include:

  • Epidemiology, detection and screening
  • Cellular research and biomarkers
  • Identification of biotargets and agents with novel mechanisms of action
  • Optimal clinical use of existing anticancer agents, including combination therapies
  • Radiation and surgery
  • Palliative care
  • Patient adherence, quality of life, satisfaction

The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.

When considering submission of a paper utilizing publicly-available data (e.g. SEER/GWAS/TCGA/GEO etc.), authors should ensure that such studies add significantly to the body of knowledge about a specific disease or relevant phenotype and that they are validated using the authors’ own data through replication in an independent sample set and functional follow-up. Bioinformatics studies should also conform to these criteria.

The journal does not consider case reports except in circumstances where they make a valuable contribution to the literature. Cell line studies must demonstrate thorough and rigorous protocols, and biomarker association studies must be supported by in vivo validations. Tissue microarray analyses and single nucleotide polymorphism (SNP) studies will not be considered.